Categories Earnings, Other Industries

Alibaba joins Cainiao aboard the ZTO Express to cut off Amazon

Chinese online retailer Alibaba Group Holding Ltd (BABA) along with its logistics partner Cainiao Network is planning to acquire a 10% stake in Shanghai-based express delivery firm ZTO Express Inc. (ZTO) for an investment of around $1.4 billion. This investment is an attempt to strengthen logistics and delivery capabilities which are becoming increasingly important for e-commerce companies. The deal will mostly close in early June.

Retailers are looking to achieve the right combination of online and offline presence in their businesses and are making the necessary investments for this purpose. Alibaba is looking to do the same through its new retail concept which aims at bringing together online and brick-and-mortar capabilities to maximize gain. The investment in ZTO is expected to benefit all three companies significantly.

Alibaba plans to invest more than $15 billion in logistics and delivery capabilities over the coming five years

Alibaba, which does not own a delivery service, has plans to invest more than $15 billion in logistics and delivery capabilities over the coming five years. The online retailer has stressed on the importance of customer service multiple times and is trying its best to improve on this area in every way it can. Improving delivery time is an integral part of this effort.

This investment will also help Alibaba gain some strength against its largest competitor JD.com which not only owns a delivery fleet but is also experimenting with new and innovative ways of delivery similar to the efforts being made by US e-commerce giant Amazon (AMZN). Alibaba ended up losing a bit of market share to its rival, and the company would definitely be looking to nip this unfavorable trend in the bud. The ZTO investment is likely to prove beneficial in this aspect.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top